FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.
What happened
FDA inspected the Wichita facility, registered as an outsourcing facility (a sterile compounder under section 503B), from June 18 to June 28, 2024, and issued a Form FDA 483 (inspection findings). Investigators found sterile drug production under insanitary conditions, including inadequate response to microbial contamination in the high-cleanliness (ISO 5) sterile processing area and production during construction without adequate contamination controls. FDA also found violations of required manufacturing quality rules (CGMP), labeling deficiencies, and noted the firm recalled four lots of Lidocaine HCl Injection 2% for lack of sterility assurance.
What FDA found
FDA found inadequate product evaluation and corrective action after microbial contamination was recovered in the ISO 5 sterile processing area, making drugs adulterated by insanitary conditions.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm produced drug products during construction without adequate controls to prevent contamination of the environment and products.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm failed to thoroughly investigate unexplained discrepancies or failures of a batch or its components to meet specifications.
21 CFR 211.192The firm failed to keep buildings used for manufacturing, processing, packing, or holding drugs clean and sanitary.
21 CFR 211.56(a)The firm failed to establish and follow written procedures to prevent microbiological contamination of sterile drugs, including validation of aseptic and sterilization processes.
21 CFR 211.113(b)Drug and container labels omitted required section 503B information such as dosage form, established drug name, active ingredients by established name, and directions for use.
FDCA section 503B(a)(10) [21 U.S.C. § 353b(a)(10)]
What FDA wants
Within 15 working days of receipt, notify FDA in writing of specific corrective steps, how recurrence will be prevented, and include supporting documents; if unable to complete, state the reason and timeline.
Who should pay attention
- hospitals and clinics that buy compounded sterile injectables
- pharmacies and brands sourcing from outsourcing facilities
- sterile compounders managing construction or contamination controls
This is a summary. Read the original letter on fda.gov.